Friday 6 November 2026 Export MRVI’s income statement to Excel — free account

Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024.

Revenue: +10.1%
EPS: +50.0%
Free cash flow: +123.9%
Total debt: −45.4%

Quarter to September 2026, against a year earlier

Insider buying

7.52 0.54 +7.74%

Follow MRVI

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: −24.4×
Dividend yield: —
F-score: 2/9
Altman Z: 0.44
Beneish M: −3.30
Dividend safety: n/a

Overview

Maravai LifeSciences Holdings, Inc. (MRVI) P/E ratio

Alert me on P/E ratio

Maravai LifeSciences Holdings, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 168× (December 2020) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/MRVI/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Maravai LifeSciences Holdings, Inc. P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/MRVI/metrics/pe-ratio">Maravai LifeSciences Holdings, Inc. (MRVI) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	8.2×	(69.48%)
FY2021	26.9×	(18.28%)
FY2020	32.9×	(79.81%)
FY2019	163×	0.00%
FY2018	163×	—

Period	P/E ratio	Change
Sep 2026	0.0×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
24 more quarters	Free account

Against its own ten years

Low 0.0× High 168×

Ten-year median 8.0×

Current reading's percentile 48

Company	P/E ratio
COAG Hemab Therapeutics Holdings, Inc. compare	n/m
MRVI Maravai LifeSciences Holdings, Inc.	n/m
TRVI Trevi Therapeutics, Inc. compare	n/m
VIR Vir Biotechnology, Inc. compare	n/m
TRAX First Tracks Biotherapeutics, Inc. compare	n/m
REPL Replimune Group, Inc. compare	n/m
FTRE Fortrea Holdings Inc. compare	n/m
SRPT Sarepta Therapeutics, Inc. compare	n/m
HRMY Harmony Biosciences Holdings, Inc. compare	10.5×
Biotechnology industry median	10.3×
Healthcare sector median	25.2×
Market median	17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

Maravai LifeSciences Holdings, Inc. (MRVI) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on MRVI

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on MRVI

Stockrow Weekly